Prognostic Progress

Gene Change Signifies Better Response to Treatment

Arnab Chakravarti 2New research proves that a change in the MGMT gene can identify which patients with glioblastoma will respond better to treatment. Testing for this gene can distinguish patients with a more- or less-aggressive form of this disease – the most common and deadliest type of primary brain cancer – and help guide therapy.

Examining the MGMT gene in tumors removed from 833 patients with glioblastoma, the researchers found that when the gene promoter is altered by a chemical change called methylation, patients respond better to treatment.

“We show that MGMT methylation represents a new genetic test that can predict clinical outcomes in glioblastoma patients treated with radiation combined with the chemotherapeutic drug temozolomide,” says co-author Arnab Chakravarti, MD, chair of Radiation Oncology and co-director of the Brain Tumor Program at the OSUCCC – James.

“Glioblastomas are a collection of different molecular and genetic entities that behave uniquely and require personalized treatment,” adds Chakravarti, who is the translational-research study chair for the study.

The findings were presented in June at the 2011 American Society of Clinical Oncology (ASCO) meeting.

To refer a patient, please call The James Line New Patient Referral Center toll free: 1-800-293-5066.

Sign up to receive publications from the OSUCCC – James

Sign Up Now

Meet the Leaders

Leadership & Executive Cabinet at The James

Learn More